Dr. Ronald H. Saff, MD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 185
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
FL license ME55004
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 185
- Services billed
- 5,310
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 4,989 | 74 |
| Established patient office or other outpatient visit, 30-39 minutes | 220 | 140 |
| Evaluation of use of breathing device | 137 | 93 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 111 | 84 |
| Test to measure the level of nitric oxide gas | 90 | 72 |
| New patient office or other outpatient visit, 45-59 minutes | 83 | 83 |
| Administration and interpretation of patient-focused health risk assessment | 65 | 58 |
| Test to measure expiratory airflow and volume | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ipratropium Bromide Other prescribers in Tallahassee, FL | 382 |
| Azelastine Hcl Other prescribers in Tallahassee, FL | 61 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Tallahassee, FL | 58 |
| Fluticasone Propionate Other prescribers in Tallahassee, FL | 57 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Tallahassee, FL | 39 |
| Breyna (budesonide/formoterol fumarate) Other prescribers in Tallahassee, FL | 34 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Tallahassee, FL | 32 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Tallahassee, FL | 32 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Tallahassee, FL | 26 |
| Montelukast Sodium Other prescribers in Tallahassee, FL | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 63 payments worth $1,887 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $430 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $321 |
| Novartis Pharmaceuticals Corporation | $218 |
| Genzyme Corporation | $217 |
| Pharming Healthcare, Inc. | $212 |
| Ars Pharmaceuticals Operations, Inc. | $106 |
| Genentech USA, Inc. | $80.84 |
| Incyte Corporation | $58.25 |
| Food and Beverage | $1,835 |
|---|---|
| Education | $51.71 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Sep 22, 2025 | Education in-kind | $34.00 |
| Regeneron Healthcare Solutions, Inc. Apr 22, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $17.71 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $195,465 in research payments for these studies, mostly to the institutions running them.
- A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label…
AstraZeneca Pharmaceuticals LP - A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
Novartis Pharmaceuticals Corporation - A phase 4, 52-week (primary analysis at 24-weeks), randomized, stratif
GlaxoSmithKline, LLC. - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP - Registry of Asthma Patients Initiating DUPIXENT®
Regeneron Pharmaceuticals, Inc. · Completed · NCT04287621 - A prospective, real-world, interventional study to evaluate the effect
GlaxoSmithKline, LLC. - A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Eli Lilly and Company · Active, not recruiting · NCT06339008 - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patient…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.